A dual role for genetically modified lymphocytes in cancer immunotherapy

Kolb, 2008, Graft-versus-leukemia effects of transplantation and donor lymphocytes, Blood, 112, 4371, 10.1182/blood-2008-03-077974 Rosenberg, 2011, Cell transfer immunotherapy for metastatic solid cancer – what clinicians need to know, Nat. Rev. Clin. Oncol., 8, 577, 10.1038/nrclinonc.2011.116 June, 2007, Principles of adoptive T cell cancer therapy, J. Clin. Invest., 117, 1204, 10.1172/JCI31446 Mackensen, 2006, Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma, J. Clin. Oncol., 24, 5060, 10.1200/JCO.2006.07.1100 Anderson, 1992, Human gene therapy, Science (New York), 256, 808, 10.1126/science.1589762 Barese, 2011, Contributions of gene marking to cell and gene therapies, Hum. Gene Ther., 22, 659, 10.1089/hum.2010.237 Seliger, 2002, HLA class I antigen abnormalities and immune escape by malignant cells, Semin. Cancer Biol., 12, 3, 10.1006/scbi.2001.0404 Eshhar, 2008, The T-body approach: redirecting T cells with antibody specificity, Handb. Exp. Pharmacol., 181, 329, 10.1007/978-3-540-73259-4_14 Vago, 2009, Loss of mismatched HLA in leukemia after stem-cell transplantation, N. Engl. J. Med., 361, 478, 10.1056/NEJMoa0811036 Kershaw, 2006, A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer, Clin. Cancer Res., 12, 6106, 10.1158/1078-0432.CCR-06-1183 Lamers, 2006, Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience, J. Clin. Oncol., 24, e20, 10.1200/JCO.2006.05.9964 Kochenderfer, 2010, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood, 116, 4099, 10.1182/blood-2010-04-281931 Porter, 2011, Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia, N. Engl. J. Med., 365, 725, 10.1056/NEJMoa1103849 Pule, 2008, Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma, Nat. Med., 14, 1264, 10.1038/nm.1882 Parmiani, 2007, Universal and stemness-related tumor antigens: potential use in cancer immunotherapy, Clin. Cancer Res., 13, 5675, 10.1158/1078-0432.CCR-07-0879 Morgan, 2006, Cancer regression in patients after transfer of genetically engineered lymphocytes, Science (New York), 314, 126, 10.1126/science.1129003 Parkhurst, 2011, T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis, Mol. Ther., 19, 620, 10.1038/mt.2010.272 Robbins, 2011, Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1, J. Clin. Oncol., 29, 917, 10.1200/JCO.2010.32.2537 Hunder, 2008, Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1, N. Engl. J. Med., 358, 2698, 10.1056/NEJMoa0800251 Lupo-Stanghellini, 2010, Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation, Hum. Gene Ther., 21, 241, 10.1089/hum.2010.014 Bonini, 2007, The suicide gene therapy challenge: how to improve a successful gene therapy approach, Mol. Ther. J. Am. Soc. Gene Ther., 15, 1248, 10.1038/sj.mt.6300190 Ciceri, 2009, Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I–II study, Lancet Oncol., 10, 489, 10.1016/S1470-2045(09)70074-9 Riddell, 1996, T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients, Nat. Med., 2, 216, 10.1038/nm0296-216 Berger, 2006, Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation, Blood, 107, 2294, 10.1182/blood-2005-08-3503 Traversari, 2007, The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies, Blood, 109, 4708, 10.1182/blood-2006-04-015230 Steinman, 2007, Taking dendritic cells into medicine, Nature, 449, 419, 10.1038/nature06175 den Haan, 2000, CD8(+) but not CD8(−) dendritic cells cross-prime cytotoxic T cells in vivo, J. Exp. Med., 192, 1685, 10.1084/jem.192.12.1685 Russo, 2007, Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity, J. Clin. Invest., 117, 3087, 10.1172/JCI30605 Fontana, 2009, Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients, Blood, 113, 1651, 10.1182/blood-2008-07-168666 Jena, 2010, Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor, Blood, 116, 1035, 10.1182/blood-2010-01-043737 Maher, 2002, Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor, Nat. Biotechnol., 20, 70, 10.1038/nbt0102-70 Milone, 2009, Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo, Mol. Ther., 17, 1453, 10.1038/mt.2009.83 Kershaw, 2002, Dual-specific T cells combine proliferation and antitumor activity, Nat. Biotechnol., 20, 1221, 10.1038/nbt756 Morgan, 2010, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2, Mol. Ther., 18, 843, 10.1038/mt.2010.24 Ertl, 2010, Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010, Cancer Res., 71, 3175, 10.1158/0008-5472.CAN-10-4035 Bendle, 2010, Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy, Nat. Med., 16, 565, 10.1038/nm.2128 Rosenberg, 2010, Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells, Mol. Ther., 18, 1744, 10.1038/mt.2010.195 Cohen, 2007, Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond, Cancer Res., 67, 3898, 10.1158/0008-5472.CAN-06-3986 Kuball, 2007, Facilitating matched pairing and expression of TCR chains introduced into human T cells, Blood, 109, 2331, 10.1182/blood-2006-05-023069 Kuball, 2005, Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR, Immunity, 22, 117, 10.1016/j.immuni.2004.12.005 Govers, 2010, T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing, Trends Mol. Med., 16, 77, 10.1016/j.molmed.2009.12.004 Okamoto, 2009, Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR, Cancer Res., 69, 9003, 10.1158/0008-5472.CAN-09-1450 Robbins, 2008, Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions, J. Immunol., 180, 6116, 10.4049/jimmunol.180.9.6116 Laugel, 2005, Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition, J. Biol. Chem., 280, 1882, 10.1074/jbc.M409427200 Varela-Rohena, 2008, Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor, Nat. Med., 14, 1390, 10.1038/nm.1779 Johnson, 2009, Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen, Blood, 114, 535, 10.1182/blood-2009-03-211714 Gattinoni, 2011, A human memory T cell subset with stem cell-like properties, Nat. Med., 17, 1290, 10.1038/nm.2446 Forster, 2008, CCR7 and its ligands: balancing immunity and tolerance, Nat. Rev. Immunol., 8, 362, 10.1038/nri2297 Bondanza, 2010, IL-7 receptor expression identifies suicide gene-modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors, Blood, 117, 6469, 10.1182/blood-2010-11-320366 Watts, 2005, TNF/TNFR family members in costimulation of T cell responses, Annu. Rev. Immunol., 23, 23, 10.1146/annurev.immunol.23.021704.115839 Bianchi, 2007, High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity, Immunol. Rev., 220, 35, 10.1111/j.1600-065X.2007.00574.x Sancho, 2009, Identification of a dendritic cell receptor that couples sensing of necrosis to immunity, Nature, 458, 899, 10.1038/nature07750 Toes, 1999, CD4 T cells and their role in antitumor immune responses, J. Exp. Med., 189, 753, 10.1084/jem.189.5.753 Boon, 2006, Human T cell responses against melanoma, Annu. Rev. Immunol., 24, 175, 10.1146/annurev.immunol.24.021605.090733 Acuto, 2008, Tailoring T-cell receptor signals by proximal negative feedback mechanisms, Nat. Rev. Immunol., 8, 699, 10.1038/nri2397 June, 2009, Engineering lymphocyte subsets: tools, trials and tribulations, Nat. Rev. Immunol., 9, 704, 10.1038/nri2635 Di Stasi, 2011, Inducible apoptosis as a safety switch for adoptive cell therapy, N. Engl. J. Med., 365, 1673, 10.1056/NEJMoa1106152 Serafini, 2004, Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease, Hum. Gene Ther., 15, 63, 10.1089/10430340460732463 Villadangos, 2007, Outside looking in: the inner workings of the cross-presentation pathway within dendritic cells, Trends Immunol., 28, 45, 10.1016/j.it.2006.12.008 Villadangos, 2010, Found in translation: the human equivalent of mouse CD8+ dendritic cells, J. Exp. Med., 207, 1131, 10.1084/jem.20100985